Improving Conventional Enhanced Permeability and Retention (EPR) Effects; What is the Appropriate Target?

Overview

Journal Theranostics

Date 2014 Jan 8

PMID 24396516

Citations 301

Authors

Hisataka Kobayashi

Rira Watanabe

Peter L Choyke

Affiliations

Soon will be listed here.

Abstract

Nano-sized therapeutic agents have several advantages over low molecular weight agents such as a larger loading capacity, the ability to protect the payload until delivery, more specific targeting due to multivalency and the opportunity for controlled/sustained release. However, the delivery of nano-sized agents into cancer tissue is problematic because it mostly relies on the enhanced permeability and retention (EPR) effect that depends on the leaky nature of the tumor vasculature and the prolonged circulation of nano-sized agents, allowing slow but uneven accumulation in the tumor bed. Delivery of nano-sized agents is dependent on several factors that influence the EPR effect; 1. Regional blood flow to the tumor, 2. Permeability of the tumor vasculature, 3. Structural barriers imposed by perivascular tumor cells and extracellular matrix, 4. Intratumoral pressure. In this review, these factors will be described and methods to enhance nano-agent delivery will be reviewed.

Citing Articles

Advances in targeted therapy for tumor with nanocarriers: A review.

Cheng H, Liao J, Ma Y, Sarwar M, Yang H Mater Today Bio. 2025; 31:101583.

PMID: 40061211 PMC: 11889621. DOI: 10.1016/j.mtbio.2025.101583.

Non-Invasive Delivery of CRISPR/Cas9 Ribonucleoproteins (Cas9 RNPs) into Cells via Nanoparticles for Membrane Transport.

Tashima T Pharmaceutics. 2025; 17(2).

PMID: 40006568 PMC: 11859894. DOI: 10.3390/pharmaceutics17020201.

Nanocarrier-mediated cancer therapy with cisplatin: .

Ranasinghe R, Mathai M, Alshawsh M, Zulli A Heliyon. 2025; 10(7):e28171.

PMID: 39839154 PMC: 11747978. DOI: 10.1016/j.heliyon.2024.e28171.

Advances in nano drug delivery systems for enhanced efficacy of emodin in cancer therapy.

Ai Z, Liu B, Chen J, Zeng X, Wang K, Tao C Int J Pharm X. 2025; 9():100314.

PMID: 39834843 PMC: 11743866. DOI: 10.1016/j.ijpx.2024.100314.

Nano-fluorescence imaging: advancing lymphatic disease diagnosis and monitoring.

Han C, Choi S, Chi S, Hong J, Cho Y, Kim J Nano Converg. 2024; 11(1):53.

PMID: 39661218 PMC: 11635084. DOI: 10.1186/s40580-024-00462-1.

References

Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P . Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. 2004; 165(1):35-52. PMC: 1618540. DOI: 10.1016/S0002-9440(10)63273-7. View

Denardo S, Kukis D, Kroger L, ODonnell R, Lamborn K, Miers L . Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci U S A. 1997; 94(8):4000-4. PMC: 20557. DOI: 10.1073/pnas.94.8.4000. View

Chauhan V, Stylianopoulos T, Martin J, Popovic Z, Chen O, Kamoun W . Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol. 2012; 7(6):383-8. PMC: 3370066. DOI: 10.1038/nnano.2012.45. View

Suzuki M, Hori K, Abe I, Saito S, Sato H . A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. J Natl Cancer Inst. 1981; 67(3):663-9. View

Maeda H . The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001; 41:189-207. DOI: 10.1016/s0065-2571(00)00013-3. View

Choi H, Liu W, Misra P, Tanaka E, Zimmer J, Ipe B . Renal clearance of quantum dots. Nat Biotechnol. 2007; 25(10):1165-70. PMC: 2702539. DOI: 10.1038/nbt1340. View

Jain R . Molecular regulation of vessel maturation. Nat Med. 2003; 9(6):685-93. DOI: 10.1038/nm0603-685. View

Maeda H . The link between infection and cancer: tumor vasculature, free radicals, and drug delivery to tumors via the EPR effect. Cancer Sci. 2013; 104(7):779-89. PMC: 7657157. DOI: 10.1111/cas.12152. View

Cyran C, Sennino B, Fu Y, Rogut V, Shames D, Chaopathomkul B . Permeability to macromolecular contrast media quantified by dynamic MRI correlates with tumor tissue assays of vascular endothelial growth factor (VEGF). Eur J Radiol. 2011; 81(5):891-6. PMC: 3242157. DOI: 10.1016/j.ejrad.2011.07.016. View

10.

Kobayashi H, Reijnders K, English S, Yordanov A, Milenic D, Sowers A . Application of a macromolecular contrast agent for detection of alterations of tumor vessel permeability induced by radiation. Clin Cancer Res. 2004; 10(22):7712-20. DOI: 10.1158/1078-0432.CCR-04-1175. View

11.

Kong G, Braun R, Dewhirst M . Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res. 2001; 61(7):3027-32. View

12.

Matsumura Y, Kataoka K . Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci. 2009; 100(4):572-9. PMC: 11158079. DOI: 10.1111/j.1349-7006.2009.01103.x. View

13.

Fang J, Nakamura H, Maeda H . The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2010; 63(3):136-51. DOI: 10.1016/j.addr.2010.04.009. View

14.

Georgi M, Freitag B . [Pharmaco-angiography of liver tumours (author's transl)]. Rofo. 1980; 132(3):287-93. DOI: 10.1055/s-2008-1056566. View

15.

Au J, Jang S, Wientjes M . Clinical aspects of drug delivery to tumors. J Control Release. 2002; 78(1-3):81-95. DOI: 10.1016/s0168-3659(01)00488-6. View

16.

Seki T, Carroll F, Illingworth S, Green N, Cawood R, Bachtarzi H . Tumour necrosis factor-alpha increases extravasation of virus particles into tumour tissue by activating the Rho A/Rho kinase pathway. J Control Release. 2011; 156(3):381-9. DOI: 10.1016/j.jconrel.2011.08.022. View

17.

Xie H, Diagaradjane P, Deorukhkar A, Goins B, Bao A, Phillips W . Integrin αvβ3-targeted gold nanoshells augment tumor vasculature-specific imaging and therapy. Int J Nanomedicine. 2011; 6:259-69. PMC: 3058535. DOI: 10.2147/IJN.S15479. View

18.

Ranjan A, Jacobs G, Woods D, Negussie A, Partanen A, Yarmolenko P . Image-guided drug delivery with magnetic resonance guided high intensity focused ultrasound and temperature sensitive liposomes in a rabbit Vx2 tumor model. J Control Release. 2012; 158(3):487-94. PMC: 3319290. DOI: 10.1016/j.jconrel.2011.12.011. View

19.

Novak D, Weber J . [Pharmaco-angiography with angiotensin (author's transl)]. Rofo. 1976; 124(4):301-9. DOI: 10.1055/s-0029-1230336. View

20.

Jang S, Wientjes M, Au J . Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule. J Pharmacol Exp Ther. 2001; 296(3):1035-42. View